SCR-LIP-000313 · Claim · machine-readable JSON →

A scoping review of 25 studies reports that lipedema symptom onset clusters at reproductive hormonal milestones (puberty/adolescence in 62.2-72.0% of cohorts, worsening in pregnancy in 53.0% and menopausal transition in 67.9%), with elevated hormone-sensitive comorbidities (PCOS 12.6-17.1%, autoimmune thyroiditis up to 35.5%) and molecular findings including loss-of-function variants in AKR1C1/AKR1C2, aromatase (CYP19A1) upregulation in adipose tissue, and altered estrogen receptor balance.

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
very low (GRADE)
Evidence
1 source(s)
Dates
2026-05-31 → 2026-05-31

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-05-31

Evidence over time

2025Lipedema in Women and Its Interrelationship with Endometriosis and Other Gynecologic Diseases: A Scoping Review — Viana et al. (2025) · consistent

Evidence (1)

Context (PECO)

Populationwomen with lipedema (25-study scoping review)
Conditionlipedema
Exposurereproductive hormonal milestones and hormone-related molecular factors
Outcomesymptom onset timing, hormonal comorbidities, molecular hormone variants
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Auto-ingested single source; not yet human-reviewed.

Change log